Effects of rosiglitazone and metformin on postprandial paraoxonase-1 and monocyte chemoattractant protein-1 in human immunodeficiency virus-infected patients with lipodystrophy

European Journal of Pharmacology

Volumn 544, Issue 1-3, 2006, Pages 104-110

  Coll, Blai ^a   van Wijk, Jeroen P H ^b   Parra, Sandra ^a   Castro Cabezas, Manuel ^b,c   Hoepelman, I M ^b   Alonso Villaverde, Carlos ^a   de Koning, Eelco J P ^d   Camps, Jordi ^a   Ferre, Natalia ^a   Rabelink, Ton J ^d   Tous, Monica ^a   Joven, Jorge ^a  

^a HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c SINT FRANCISCUS GASTHUIS   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

HIV; Metformin; Monocyte chemoattractant protein 1; Paraoxonase; Postprandial; Rosiglitazone

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; C REACTIVE PROTEIN; FAT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 6; METFORMIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NUCLEOSIDE DERIVATIVE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSIGLITAZONE;

ADULT; ANALYTICAL PARAMETERS; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMORBIDITY; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DRUG EFFECT; HEART PROTECTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMEOSTASIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; INSULIN RESISTANCE; LIPODYSTROPHY; LOADING TEST; MALE; PARAMETERS OF MEASUREMENT AND ANALYSIS; PLASMA; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; TREATMENT DURATION;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; ARYLDIALKYLPHOSPHATASE; CHEMOKINE CCL2; CHOLESTEROL, HDL; HIV; HIV INFECTIONS; HUMANS; HYPOGLYCEMIC AGENTS; LIPODYSTROPHY; MALE; METFORMIN; MIDDLE AGED; POSTPRANDIAL PERIOD; THIAZOLIDINEDIONES;

EID: 33746769423     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.06.014     Document Type: Article

References (40)

1. Alonso-Villaverde C., Coll B., Parra S., Montero M., Calvo N., Tous M., Joven J., and Masana L. Atherosclerosis in patients infected with HIV is influenced by a mutant monocyte chemoattractant protein-1 allele. Circulation 110 (2004) 2204-2209
2. Balasubramanyam A., Sekhar R.V., Jahoor F., Jones P.H., and Pownall H.J. Pathophysiology of dyslipidemia and increased cardiovascular risk in HIV lipodystrophy: a model of "systemic steatosis". Curr. Opin. Lipidol. 15 (2004) 59-67
3. Carr A., Samaras K., Burton S., Law M., Freund J., Chisholm D.J., and Cooper D.A. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12 (1998) F51-F58
4. Carr A., Workman C., Carey D., Rogers G., Martin A., Baker D., Wand H., Law M., Samaras K., Emery S., Cooper D.A., and Rosey investigators. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet 363 (2004) 429-438
5. Ceriello A., Quagliaro L., Piconi L., Assaloni R., Da Ros R., Maier A., Esposito K., and Giugliano D. Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment. Diabetes 53 (2004) 701-710
6. Ceriello A., Assaloni R., Da Ros R., Maier A., Piconi L., and Quagliaro L. Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients. Circulation 111 (2005) 2518-2524
7. Christiansen T., Richelsen B., and Bruun J.M. Monocyte chemoattractant protein-1 is produced in isolated adipocytes, associated with adiposity and reduced after weight loss in morbid obese subjects. Int. J. Obes. Relat. Metab. Disord. 29 (2005) 146-150
8. Deo R., Khera A., McGuire D.K., Murphy S.A., Meo Neto J.P., Morrow D.A., and de Lemos J.A. Association among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk factors, and subclinical atherosclerosis. J. Am. Coll. Cardiol. 44 (2004) 1812-1818
9. Dolan S.E., Hadigan C., Killilea K.M., Sulllivan M.P., Hemphill L., and Lees R.S. Increased cardiovascular disease risk indices in HIV-infected women. J. Acquir. Immune Defic. Syndr. 39 (2005) 44-54
10. Domoto K., Taniguchi T., Takaishi H., Takahashi T., Fujioka Y., Takahashi A., Ishikawa Y., and Yokoyama M. Chylomicron remnants induce monocyte chemoattractant protein-1 expression via p38 MAPK activation in vascular smooth muscle cells. Atherosclerosis 171 (2003) 193-200
11. Durrington P.N., Mackness B., and Mackness M.I. Paraoxonase and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 473-480
12. Ferré N., Camps J., Fernández-Ballart J., Arija V., Murphy M.M., Ceruelo S., Biarnes E., Vilella E., Tous M., and Joven J. Regulation of serum paraoxonase activity by genetic, nutritional, and lifestyle factors in the general population. Clin. Chem. 49 (2003) 1491-1497
13. Friis-Moller N., Sabin C.A., Weber R., d'Arminio Monforte A., El-Sadr W.M., Reiss P., Thiebaut R., Morfeldt L., De Wit S., Pradier C., Calvo G., Law M.G., Kirk O., Phillips A.N., Lundgren J.D., and Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N. Engl. J. Med. 349 (2003) 1993-2003
14. Groot P.H., van Stiphout W.A., Krauss X.H., Jansen H., van Tol A., van Ramshorst E., Chin-On S., Hofman A., Cresswell S.R., and Havekes L. Postprandial lipoprotein metabolism in normolipidemic men with and without coronary artery disease. Arterioscler. Thromb. 11 (1991) 653-662
15. Gu L., Rutledge B., Fiorillo J., Ernst C., Grewal I., Flavell R., Gladue R., and Rollins B. In vivo properties of monocyte chemoattractant protein-1. J. Leukoc. Biol. 62 (1997) 577-580
16. Hadigan C., Corcoran C., Basgoz N., Davis B., Sax P., and Grinspoon S. Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial. JAMA 284 (2000) 472-477
17. Hadigan C., Meigs J.B., Corcoran C., Rietschel P., Pieuch S., and Basgoz N. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin. Infect. Dis. 32 (2001) 130-139
18. Hadigan C., Rabe J., and Grinspoon S. Sustained benefits of metformin therapy on markers of cardiovascular risk in human immunodeficiency virus-infected patients with fat redistribution and insulin resistance. J. Clin. Endocrinol. Metab. 87 (2002) 4611-4615
19. Hadigan C., Yawetz S., Thomas A., Havers F., Sax P.E., and Grinspoon S. Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial. Ann. Intern. Med. 140 (2004) 786-794
20. Haffner S.M., Greenberg A.S., Weston W.M., Chen H., Williams K., and Freed M. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106 (2002) 679-684
21. Hundal R.S., and Inzucchi S.E. Metformin: new understandings, new uses. Drugs 63 (2003) 1879-1894
22. Libby P., and Ridker P.M. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am. J. Med. 116 Suppl 6A (2004) 9S-16S
23. Mackness M.I., Arrol S., Abbot C., and Durrington P.N. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 104 (1993) 129-135
24. Mackness B., Mackness M.I., Arrol S., Turkie W., Julier K., Abuasha B., Miller J.E., Boulton A.J., and Durrington P.N. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis 139 (1998) 341-349
25. Mackness B., Durrington P.N., Abuashia B., Boulton A.J., and Mackness M.I. Low paraoxonase activity in type II diabetes complicated by retinopathy. Clin. Sci. 98 (2000) 355-363
26. Mackness B., Hine D., Liu Y., Mastorikou M., and Mackness M. Paraoxonase-1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells. Biochem. Biophys. Res. Commun. 318 (2004) 680-683
27. Mohanty P., Aljada A., Ghanim H., Hofmeyer D., Tripathy D., Syed T., Al-Haddad W., Dhindsa S., and Dandona P. Evidence for a potent antiinflammatory effect of rosiglitazone. J. Clin. Endocrinol. Metab. 89 (2004) 2728-2735
28. Palella Jr. F.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., Aschman D.J., and Holmberg S.D. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. 338 (1998) 853-860
29. Ross R. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 340 (1999) 115-126
30. Saint-Marc T., and Touraine J.L. Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy. AIDS 13 (1999) 1000-1002
31. Senti M., Tomas M., Fito M., Weinbrenner T., Covas M.I., Sala J., Masia R., and Marrugat J. Antioxidant paraoxonase 1 activity in the metabolic syndrome. J. Clin. Endocrinol. Metab. 88 (2003) 5422-5426
32. Shamir R., Shehadeh N., Rosenblat M., Eshach-Adiv O., Coleman R., Kaplan M., Hamoud S., Lischinsky S., and Hayek T. Oral insulin supplementation attenuates atherosclerosis progression in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 104-110
33. Shih D.M., Gu L., Xia Y.R., Navab M., Li W.F., Hama S., Castellani L.W., Furlong C.E., Costa L.G., Fogelman A.M., and Lusis A.J. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394 (1998) 284-287
34. Stein J.H., Merwood M.A., Bellehumeur J.B., McBride P.E., Wiebe D.A., and Sosman J.M. Postprandial lipoprotein changes in patients taking antiretroviral therapy for HIV infection. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 399-405
35. Sutinen J., Hakkinen A.M., Westerbacka J., Seppala-Lindroos A., Vehkavaara S., Halavaara J., Jarvinen A., Ristola M., and Yki-Jarvinen H. Rosiglitazone in the treatment of HAART-associated lipodystrophy: a randomized double-blind placebo-controlled study. Antivir. Ther. 8 (2003) 199-207
36. van Oostrom A.J., Sijmonsma T.P., Verseyden C., Jansen E.H., de Koning E.J., Rabelink T.J., and Castro Cabezas M. Postprandial recruitment of neutrophils may contribute to endothelial dysfunction. J. Lipid Res. 44 (2003) 576-583
37. van Wijk J.P.H., de Koning E.J.P., Castro Cabezas M., Roodt J., Joven J., Rabelink T.J., and Hoepelman A. Comparison of rosiglitazone and metformin for treating HIV-lipodystrophy: a randomized trial. Ann. Intern. Med. 143 (2005) 337-346
38. Weintraub M.S., Grosskopf I., Rassin T., Miller H., Charach G., Rotmensch H.H., Liron M., Rubinstein A., and Iaina A. Clearance of chylomicron remnants in normolipidaemic patients with coronary artery disease: case control study over three years. BMJ 312 (1996) 936-939
39. Yamada A., Shoji T., Tahara H., Emoto M., and Nishizawa Y. Effect of insulin resistance on serum paraoxonase activity in a nondiabetic population. Metabolism 50 (2001) 805-811
40. Yki-Jarvinen H. Thiazolidinediones. N. Engl. J. Med. 351 (2004) 1106-1118